Patient information

LOLIPOP Trial Summary

 

The problem

Following breast cancer surgery, nearly half of women will continue to have some degree of persistent or chronic pain. This pain can be mild, but up to a quarter of patients may have moderate or severe pain.

The potential solution

Lidocaine is an approved local anaesthetic drug, but it’s not currently approved to prevent pain after breast cancer surgery.

The LOLIPOP team completed a pilot study of 150 patients, showing that lidocaine infusions are safe. We are now undertaking the LOLIPOP trial to see if it is an effective treatment to reduce chronic post-surgical pain.

What to expect as a participant

Patients undergoing breast cancer surgery who consent to the trial will be randomly assigned to either receive Lidocaine (a common local anaesthetic drug) or placebo (saltwater with no drug) infusion for up to 24 hours post breast cancer surgery.

During the operation, the study drug will be delivered by a cannula (a drip; or small plastic tube in a vein). If you are staying in hospital overnight, the study drug will continue to be delivered for up to 24 hours by a cannula just under the skin in the stomach.

Patients will be asked questions about their pain whilst they are in hospital, and at 3, 6 and 12 months post surgery.

Watch our Patient Information Video to find out more

You can also read our Patient Information Leaflet below

LOLIPOP-UK_Patient Information Leaflet v3.0